Faculty profile
Blair Leavitt
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Restricting lysine normalizes toxic catabolites associated with ALDH7A1 deficiency in cells and mice.
Cell reports · 2024
Natural biological variation of white matter microstructure is accentuated in Huntington's disease.
Human brain mapping · 2018
Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study.
NeuroImage. Clinical · 2018
Latest funding
- $333,000
Exploring the impact of somatic expansion rates on quantitative progression marker candidates (Voice) in early stages of Repeat Expansion Disorders Expand-RED: JPND2024-236
CIHR · 2024 · Nominated PI
- $761,176
Lipid Nanoparticle-Mediated Delivery of CRISPR/Cas9 Gene Editing for Neurological Disorders.
CIHR · 2022 · Nominated PI
- $100,000
Lipid Nanoparticle-Mediated Delivery of CRISPR/Cas9 Gene Editing for Neurological Disorders.
CIHR · 2021 · Nominated PI
7 publications.
Restricting lysine normalizes toxic catabolites associated with ALDH7A1 deficiency in cells and mice.
Johal AS, Al-Shekaili HH, Abedrabbo M, Kehinde AZ, Towriss M, Koe JC, Hewton KG, Thomson SB, Ciernia AV, Leavitt B, Parker SJ
Natural biological variation of white matter microstructure is accentuated in Huntington's disease.
Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M
Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study.
Baake V, Coppen EM, van Duijn E, Dumas EM, van den Bogaard SJA, Scahill RI, Johnson H, Leavitt B, Durr A, Tabrizi SJ, Craufurd D, Roos RAC, Track-HD investigators
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E
A Computational Cognitive Biomarker for Early-Stage Huntington's Disease.
Wiecki TV, Antoniades CA, Stevenson A, Kennard C, Borowsky B, Owen G, Leavitt B, Roos R, Durr A, Tabrizi SJ, Frank MJ
Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.
Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C
Exploring the impact of somatic expansion rates on quantitative progression marker candidates (Voice) in early stages of Repeat Expansion Disorders Expand-RED: JPND2024-236
Principal investigators: Leavitt, Blair R
Keywords: Biomarkers; Digital Phenotyping; Huntington'S Disease; Mr Imaging; Nanopore Long Read Sequencing; Quantitative Trait; Repeat Expansion Disorders; Somatic Expansion
Lipid Nanoparticle-Mediated Delivery of CRISPR/Cas9 Gene Editing for Neurological Disorders.
Principal investigators: Leavitt, Blair R
Keywords: Crispr/Cas9; Frontotemporal Dementia; Gene Therapy; Genome Editing; Lipid Nanoparticles; Nanotechnology; Neurodegeneration; Nucleic Acid Therapeutics; Progranulin; Transgenic Mice
Lipid Nanoparticle-Mediated Delivery of CRISPR/Cas9 Gene Editing for Neurological Disorders.
Principal investigators: Leavitt, Blair R
Keywords: Crispr/Cas9; Frontotemporal Dementia; Gene Therapy; Genome Editing; Lipid Nanoparticles; Nanotechnology; Neurodegeneration; Nucleic Acid Therapeutics; Progranulin; Transgenic Mice
Characterization and treatment of a novel conditional mouse model of pyridoxine-dependent epileptic encephalopathy caused by antiquitin mutations.
Principal investigators: Leavitt, Blair R
Keywords: Antiquitin Gene (Aldh7a1); Electroencephalography; Epilepsy; Epileptic Encephalopathies; Intellectual Disability; Lysine Catabolism Pathway; Mouse Models; Neurodevelopmental Delay; Pyridoxine-Dependent Epilepsy; Seizures
CHAnging Rare disorders of LysInE metabolism
Principal investigators: Leavitt, Blair R
Keywords: Animal Models; Antisense Oligonucleotides; Disease Biomarkers; Gene Therapy; Glutaric Aciduria 1; Lysine Metabolism; Pyridoxine-Dependent Epilepsy; Small Molecule Inhibitors
Development, characterization and treatment of a novel conditional mouse model of pyridoxine-dependent epileptic encephalopathy caused by antiquitin mutations.
Principal investigators: Leavitt, Blair R
Keywords: Antiquitin (Atq) Gene; Electroencephalography; Epilepsy; Epileptic Encephalopathies; Intellectual Disability; Lysine Catabolism Pathway; Mouse Models; Neurodevelopmental Delay; Pyridoxine-Dependent Epilepsy; Seizures
Novel Approaches Directed to Prevention and Treatment of Huntington Disease
Principal investigators: Hayden, Michael R
Keywords: Animal Models; Drug Deliveries System; Excitotoxicity; Gene Silencing; Huntington Disease; Novel Pathways; Proteolysis
Functional Characterization of the Huntingtin Gene Promoter
Principal investigators: De Souza, Rebecca A
Keywords: Genetics; High Throughput Screening; Luciferase Assay; Neurology; Promoter Function; Tissue Culture
In Vivo Studies to define the Role of Progranulin Mutations in Frontotemporal Dementia
Principal investigators: Leavitt, Blair R
Keywords: Dementia; Mouse Models; Neurodegeneration; Progranulin
Determination of muscle properties that alter ALS onset and disease progression using the G93A mouse model of ALS
Principal investigators: Leavitt, Blair R
Keywords: Amyotrophic Lateral Sclerosis; Gene Transfer; Muscle; Mutant G93a Sod1 Transgenic Mice; Neuromuscular; Transgenic Mouse Models
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.